<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1718_S10_C09EM_p223-240</title>
		<link href="BCSC1718_S10_C09EM_p223-240-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1718_S10_C09EM_p223-240" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="em-only_endmatter-title">Basic Texts</p>
			<p class="em-only_endmatter-h1 ParaOverride-1">Glaucoma</p>
			<p class="em-only_endmatter-reference">Allingham RR, Damji KF, Freedman S, Maroi SE, Rhee DJ. <span class="CharOverride-1">Shields’</span> <span class="CharOverride-1">Textbook of Glaucoma</span>. 6th ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2010.</p>
			<p class="em-only_endmatter-reference">Anderson DR, Patella VM. <span class="CharOverride-1">Automated Static Perimetry</span>. 2nd ed. St Louis: Mosby; 1998.</p>
			<p class="em-only_endmatter-reference">Epstein DL, Allingham RR, Schuman JS, eds. <span class="CharOverride-1">Chandler and Grant’s Glaucoma</span>. 4th ed. Baltimore: Lippincott Williams &amp; Wilkins; 1997.</p>
			<p class="em-only_endmatter-reference">Levin LA, Nilsson SFE, Ver Hoeve J, Wu SM, Kaufman PL, Alm A. <span class="CharOverride-1">Adler’s Physiology of the Eye: Clinical Application.</span> 11th ed. New York: Saunders/Elsevier; 2011.</p>
			<p class="em-only_endmatter-reference">Ritch R, Shields MB, Krupin T, eds. <span class="CharOverride-1">The Glaucomas</span>. 2nd ed. St Louis: Mosby; 1996.</p>
			<p class="em-only_endmatter-reference">Stamper RL, Lieberman MF, Drake MV, eds. <span class="CharOverride-1">Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas</span>. 8th ed. St Louis: Mosby; 2009.</p>
			<p class="em-only_endmatter-reference">Tasman W, Jaeger EA, eds. <span class="CharOverride-1">Duane’s Ophthalmology on DVD-ROM. </span>Philadelphia: Lippincott Williams &amp; Wilkins; 2012.</p>
			<p class="em-only_endmatter-reference">Weinreb RN, Mills RP, eds. <span class="CharOverride-1">Glaucoma Surgery: Principles and Techniques. </span>2nd ed. Ophthalmology Monographs 4. San Francisco: American Academy of Ophthalmology; 1998.</p>
			<p class="em-only_endmatter-reference _idGenParaOverride-1">Zimmerman TJ, Kooner KS, Fechtner RD, Sharir M. <span class="CharOverride-1">Textbook of Ocular Pharmacology</span>. 3rd ed. Philadelphia: Lippincott Williams &amp; Wilkins; 1997.</p>
			<p class="em-only_endmatter-title">Related Academy Materials</p>
			<p class="body-text--no-indent- ParaOverride-2">The American Academy of Ophthalmology is dedicated to providing a wealth of high-quality clinical education resources for ophthalmologists. </p>
			<p class="fm-only_fm-h2">Print Publications and Electronic Products</p>
			<p class="body-text--no-indent- ParaOverride-2">For a complete listing of Academy products related to topics covered in this BCSC Section, visit our online store at http://store.aao.org/clinical-education/topic/glaucoma.html. Or call Customer Service at 866.561.8558 (toll free, US only) or +1 415.561.8540, Monday through Friday, between 8:00 <span class="CharOverride-2">am</span> and 5:00 <span class="CharOverride-2">pm</span> (PST). </p>
			<p class="fm-only_fm-h2">Online Resources</p>
			<p class="body-text--no-indent-">Visit the Ophthalmic News and Education (ONE®) Network at aao.org/onenetwork to find relevant videos, online courses, journal articles, practice guidelines, self-assessment quizzes, images and more. The ONE Network is a free Academy-member benefit.</p>
			<p class="body-text ParaOverride-3">Access free, trusted articles and content with the Academy’s collaborative online encyclopedia, EyeWiki, at aao.org/eyewiki.</p>
			<p class="em-only_endmatter--form-tx- ParaOverride-4"><span class="CharOverride-3">Requesting Continuing Medical Education Credit</span></p>
			<p class="em-only_endmatter--form-tx- ParaOverride-1"><span class="CharOverride-4">The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</span></p>
			<p class="em-only_endmatter--form-tx-"><span class="CharOverride-4">The American Academy of Ophthalmology designates this enduring material for a maximum of 10 </span><span class="CharOverride-5">AMA PRA Category 1 Credits</span><span class="CharOverride-6">™</span><span class="CharOverride-4">. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</span></p>
			<p class="em-only_endmatter--form-tx-"><span class="CharOverride-4">The American Medical Association requires that all learners participating in activities involving enduring materials complete a formal assessment before claiming continuing medical education (CME) credit. To assess your achievement in this activity and ensure that a specified level of knowledge has been reached, a posttest for this Section of the Basic and Clinical Science Course is provided online. A minimum score of 80% must be obtained to pass the test and claim CME credit.</span></p>
			<p class="em-only_endmatter--form-tx-"><span class="CharOverride-7">To take the posttest and request CME credit online: </span></p>
			<p class="em-only_endmatter--form-nl- ParaOverride-5"><span class="CharOverride-4">1.&#9;Go to www.aao.org/cme-central and log in.</span></p>
			<p class="em-only_endmatter--form-nl- ParaOverride-6"><span class="CharOverride-4">2.&#9;Click on “Claim CME Credit and View My CME Transcript” and then “Report AAO Credits.”</span></p>
			<p class="em-only_endmatter--form-nl- ParaOverride-6"><span class="CharOverride-4">3.&#9;Select the appropriate media type and then the Academy activity. You will be directed to the posttest.</span></p>
			<p class="em-only_endmatter--form-nl- ParaOverride-7"><span class="CharOverride-4">4.&#9;Once you have passed the test with a score of 80% or higher, you will be directed to your transcript. </span><span class="CharOverride-5">If you are not an Academy member, you will be able to print out a certificate of participation once you have passed the test.</span></p>
			<p class="em-only_endmatter--form-tx- ParaOverride-8"><span class="CharOverride-4">CME expiration date: June 1, 2019. </span><span class="CharOverride-5">AMA PRA Category 1 Credits</span><span class="CharOverride-6">™</span><span class="CharOverride-4"> may be claimed only once between June 1, 2016, and the expiration date.</span></p>
			<p class="em-only_endmatter--form-tx- ParaOverride-9"><span class="CharOverride-4">For assistance, contact the Academy’s Customer Service department at 866-561-8558 (US&#160;only) or </span><span class="CharOverride-4">+1 </span><span class="CharOverride-4">415-561-8540 between 8:00 </span><span class="CharOverride-8">am</span><span class="CharOverride-4"> and 5:00 </span><span class="CharOverride-8">pm</span><span class="CharOverride-4"> (PST), Monday through Friday, or send an e-mail to &#173;customer_service@aao.org.</span></p>
			<p class="em-only_endmatter-title">Study Questions</p>
			<p class="em-only_endmatter-sq-text"><span class="CharOverride-9">Please note that these questions are not part of your CME reporting process. They are provided here for your own educational use and identification of any professional practice gaps. The required CME posttest is available online (see “Requesting CME Credit”). Following the questions are a blank answer sheet and answers with discussions. Although a concerted effort has been made to avoid ambiguity and redundancy in these questions, the authors recognize that differences of opinion may occur regarding the “best” answer. The discussions are provided to demonstrate the rationale used to derive the answer. They may also be helpful in confirming that your approach to the problem was correct or, if necessary, in fixing the principle in your memory. </span></p>
			<p class="em-only_endmatter-sq-question">&#9;1.&#9;Prospective trials have found several risk factors for the development or progression <br />of primary open-angle glaucoma (POAG). What factor is associated with a critical risk of progression in POAG?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;young age</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;thicker cornea </p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;decreased perfusion pressure </p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;elevated intracranial pressure</p>
			<p class="em-only_endmatter-sq-question">&#9;2.&#9;What is the mode of inheritance of Axenfeld-Rieger syndrome? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;X-linked</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;sporadic</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;autosomal recessive</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;autosomal dominant</p>
			<p class="em-only_endmatter-sq-question">&#9;3.&#9;Which parameter of the modified Goldmann equation cannot be directly measured clinically and must be calculated from the other parameters of this equation? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;outflow facility</p>
			<p class="em-only_endmatter-sq-question-choice">b.&#9;aqueous humor formation rate </p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;uveoscleral flow rate</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;episcleral venous pressure</p>
			<p class="em-only_endmatter-sq-question">&#9;4.&#9;What is the rate of aqueous humor formation during sleep, compared with the rate during waking hours?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;the same as during waking hours </p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;decreased by approximately 50% </p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;increased by approximately 50%</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;increased by 25%</p>
			<p class="em-only_endmatter-sq-question">&#9;5.&#9;What type of tonometer utilizes the Imbert-Fick principle for measurement of intraocular pressure (IOP)? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;pneumatonometer</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;Schiøtz tonometer</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;Perkins tonometer</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;dynamic contour tonometer</p>
			<p class="em-only_endmatter-sq-question">&#9;6.&#9;When is a false-positive error recorded in perimetry?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;when the patient responds even though no visual stimulus was presented</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;when the patient moves his or her eyes from the central fixation point</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;when, on retesting, the patient does not respond to a stimulus that was previously seen</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;when the patient falsely responds to a visual stimulus presented in the blind spot </p>
			<p class="em-only_endmatter-sq-question">&#9;7.&#9;What is the best way to examine the optic nerve head (also called optic disc) in routine clinical practice? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;with a slit-lamp biomicroscope and a high-magnification (eg, 60.00, 78.00, or 90.00 D) posterior pole lens </p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;with the indirect ophthalmoscope</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;with the direct ophthalmoscope and low magnification</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;with the direct ophthalmoscope and high magnification</p>
			<p class="em-only_endmatter-sq-question">&#9;8.&#9;What is the criterion that was used in the Ocular Hypertension Treatment Study (OHTS) for identification of a visual field defect on standard automated perimetry?<span class="CharOverride-10"> </span></p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;presence of a Glaucoma Hemifield Test (GHT) with abnormally low sensitivity</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;presence of a Pattern Standard Deviation (PSD) with <span class="CharOverride-1">P</span><span class="CharOverride-9"> &lt; 5% or presence of a GHT with a result outside normal limits</span></p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;presence of a cluster of 2 abnormal points on the pattern deviation plot</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;diffuse loss of sensitivity with a mean deviation with <span class="CharOverride-1">P</span><span class="CharOverride-9"> &lt; 5%</span></p>
			<p class="em-only_endmatter-sq-question">&#9;9.&#9;Mutations in which gene are associated with pseudoexfoliation syndrome?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;<span class="CharOverride-1">CYP1B1</span></p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;<span class="CharOverride-1">FOXC1</span></p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;<span class="CharOverride-1">LOXL1</span></p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;<span class="CharOverride-1">PITX2</span></p>
			<p class="em-only_endmatter-sq-question">&#9;10.&#9;What is the most common cause of glaucoma associated with primary or metastatic <br />tumors of the ciliary body?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;angle closure by rotation of the ciliary body</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;deposition of tumor cells and inflammatory cells in the trabecular meshwork</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;direct invasion of the anterior chamber angle</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;neovascularization of the angle</p>
			<p class="em-only_endmatter-sq-question">&#9;11.&#9;Which type of glaucoma is caused by leakage of lens protein through the capsule of a mature or hypermature cataract? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;phacomorphic glaucoma</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;lens particle glaucoma</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;ectopia lentis</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;phacolytic glaucoma</p>
			<p class="em-only_endmatter-sq-question">&#9;12.&#9;In the assessment of a patient with acute bilateral angle closure and a normal axial length, what additional step is critical to reaching an accurate diagnosis? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;Perform an immediate bilateral paracentesis.</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;Perform iris angiography.</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;Take a medication history.</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;Perform ultrasound biomicroscopy.</p>
			<p class="em-only_endmatter-sq-question">&#9;13.&#9;Peripheral iridotomy is the treatment of choice for what disorder?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;secondary angle closure following dense panretinal photocoagulation</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;iridocorneal endothelial dystrophy</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;phacoanaphylactic glaucoma</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;phacomorphic glaucoma</p>
			<p class="em-only_endmatter-sq-question">&#9;14.&#9;What is the most important factor in determining when to perform a laser peripheral iridotomy in an eye with a narrow angle?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;gonioscopic findings</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;amount of glaucomatous optic nerve cupping</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;amount of glaucomatous visual field loss</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;IOP level</p>
			<p class="em-only_endmatter-sq-question">&#9;15.&#9;What type of primary angle closure (PAC) occurs independent of pupillary block?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;acute PAC</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;intermittent PAC</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;plateau iris syndrome</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;subacute PAC</p>
			<p class="em-only_endmatter-sq-question">&#9;16.&#9;What type of glaucoma is unlikely to resolve after cataract extraction?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;primary angle-closure glaucoma</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;phacolytic glaucoma</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;an eye with angle recession and phacodonesis after blunt trauma </p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;microspherophakia with glaucoma</p>
			<p class="em-only_endmatter-sq-question">&#9;17.&#9;What finding<span class="CharOverride-10"> </span><span class="CharOverride-9">on examination of a patient with congenital glaucoma can continue to change</span><span class="CharOverride-9"> and indicate progressive glaucoma even though the IOP appears to be controlled?</span></p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;axial length </p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;corneal thickness</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;gonioscopic findings</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;myopia</p>
			<p class="em-only_endmatter-sq-question">&#9;18.&#9;After successful surgery for congenital glaucoma, for how many years should a child be monitored? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;5 years</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;10 years</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;20 years</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;for life </p>
			<p class="em-only_endmatter-sq-question">&#9;19.&#9;What glaucoma medication is contraindicated in the treatment of glaucoma in a toddler?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;brimonidine</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;dorzolamide</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;latanoprost</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;timolol</p>
			<p class="em-only_endmatter-sq-question">&#9;20.&#9;Which class of ocular hypotensive agents is associated with the development of apnea in infants and young children?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;α<span class="CharOverride-11">2</span>-selective adrenergic agonists</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;nonselective β-antagonists</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;carbonic anhydrase inhibitors</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;cholinergic agonists</p>
			<p class="em-only_endmatter-sq-question">&#9;21.&#9;Compared with nonselective adrenergic antagonists, which topical β<span class="CharOverride-11">1</span>-selective adrenergic antagonist is less likely to induce bronchospasm in patients with mild asthma?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;timolol</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;carteolol</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;betaxolol</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;levobunolol</p>
			<p class="em-only_endmatter-sq-question">&#9;22.&#9;In a patient undergoing trabeculectomy for a preoperative IOP of 50 mm Hg, which crystalline lens status and postoperative IOP level pose the greatest risk for development of a suprachoroidal hemorrhage? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;phakic eye<span class="CharOverride-10"> </span><span class="CharOverride-9">with a postoperative IOP in the mid teens</span></p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;phakic eye with a postoperative IOP in the single digits</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;aphakic eye with a postoperative IOP in the mid teens</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;aphakic eye with a postoperative IOP in the single digits</p>
			<p class="em-only_endmatter-sq-question">&#9;23.&#9;Five years after laser trabeculoplasty, what percentage of treated patients are expected to maintain a lower IOP? </p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;20%</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;30%</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;40%</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;50%</p>
			<p class="em-only_endmatter-sq-question">&#9;24.&#9;Who is the best candidate for a trabeculectomy with mitomycin C?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;aphakic contact lens wearer</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;patient with neovascular glaucoma</p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;patient with previous failed trabeculectomy without antifibrotics</p>
			<p class="em-only_endmatter-sq-question-choice">d. &#9;patient with active uveitis</p>
			<p class="em-only_endmatter-sq-question">&#9;25.&#9;What patient profile has the most success with laser trabeculoplasty?</p>
			<p class="em-only_endmatter-sq-question-choice">a. &#9;aphakic patient who is intolerant of multiple medications and whose current IOP is above the target pressure</p>
			<p class="em-only_endmatter-sq-question-choice">b. &#9;patient with a 10<span class="CharOverride-12">°</span> central island of vision who is on maximally tolerated core medical therapy </p>
			<p class="em-only_endmatter-sq-question-choice">c. &#9;patient with POAG who is intolerant of multiple medications and whose current IOP is above the target pressure</p>
			<p class="em-only_endmatter-sq-question-choice _idGenParaOverride-1">d. &#9;patient with uveitic glaucoma </p>
			<p class="em-only_endmatter-title">Answer Sheet for Section 10 <br />Study Questions</p>
			<table id="table001" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tch"><span class="CharOverride-12">Question</span></p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tch"><span class="CharOverride-12">Answer</span></p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tch"><span class="CharOverride-12">Question</span></p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tch"><span class="CharOverride-12">Answer</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 1</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">14</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 2</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">15</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 3</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">16</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 4</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">17</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 5</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">18</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 6</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">19</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 7</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">20</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 8</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">21</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10"> 9</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">22</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">10</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">23</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">11</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">24</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">12</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">25</p>
						</td>
						<td class="Basic-Table CellOverride-2">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">13</p>
						</td>
						<td class="Basic-Table CellOverride-1">
							<p class="em-only_em-ans-tb ParaOverride-10">a b c d</p>
						</td>
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-1" />
						<td class="Basic-Table CellOverride-2" />
					</tr>
				</tbody>
			</table>
			<p class="em-only_endmatter-title">Answers</p>
			<p class="em-only_endmatter-answers">&#9;1.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> In prospective trials, decreased perfusion pressure, thinner cornea, and increasing age have been shown to be important risk factors for progression of glaucoma. Intracranial pressure may have an effect on the translaminar pressure gradient but has not been studied in clinical trials. Furthermore, lower intracranial pressure has been implicated as a factor in low-tension glaucoma but has not been explored in a longitudinal trial.</span></p>
			<p class="em-only_endmatter-answers">&#9;2.&#9;<span class="CharOverride-10">d. </span><span class="CharOverride-9">Axenfeld-Rieger syndrome is an autosomal dominant disorder and presents with a variety of phenotypes. </span></p>
			<p class="em-only_endmatter-answers">&#9;3.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> Outflow facility is measured with tonography; aqueous humor formation rate, with fluorophotometry; and episcleral venous pressure, with venomanometry. All of these procedures are noninvasive. In contrast, direct measurement of uveoscleral flow rate is an invasive process that involves perfusion of a tracer into the anterior segment of the eye, followed by estimation of the tissue distribution of the tracer. Thus, in humans, uveoscleral outflow rate must be calculated by using the Goldmann equation and the parameters intraocular pressure (IOP), aqueous humor flow rate, outflow facility, and episcleral venous pressure.</span></p>
			<p class="em-only_endmatter-answers">&#9;4.&#9;<span class="CharOverride-10">b.</span><span class="CharOverride-9"> </span><span class="CharOverride-9">During waking hours, the rate of aqueous humor formation is normally about <br />2–3 μL/min. </span><span class="CharOverride-9">During sleep, the rate decreases by approximately 50%. There are no known cases of glaucoma that are caused by overproduction of aqueous humor.</span></p>
			<p class="em-only_endmatter-answers">&#9;5.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> Like the Goldmann tonometer, the Perkins tonometer is an applanation tonometer and, as such, is based on the Imbert-Fick principle. The Imbert-Fick principle relates the pressure inside a dry, thin-walled sphere to the force required to flatten a specific area. The Goldmann applanation tonometer and the Perkins tonometer use the same measurement </span><span class="CharOverride-9">tip, which balances surface tension of the tear film with the rigidity of the cornea to ap</span><span class="CharOverride-9">proximate a dry, infinitely flexible, thin-walled sphere for eyes with corneal thickness of 520 μm.</span></p>
			<p class="em-only_endmatter-answers">&#9;6.&#9;<span class="CharOverride-10">a.</span><span class="CharOverride-9"> A false-positive occurs when the patient presses the button and shows a response without presentation of any visual stimulus. </span></p>
			<p class="em-only_endmatter-answers">&#9;7.&#9;<span class="CharOverride-10">a.</span><span class="CharOverride-9"> A slit-lamp biomicroscope and a high-magnification posterior pole lens allow stereoscopic and detailed routine examination of the optic nerve head. The direct ophthalmoscope also may be used for clinical examination of the optic nerve head. However, this instrument may not provide sufficient stereoscopic detail to detect subtle changes in optic nerve head topography. Indirect ophthalmoscopy provides a low-magnification view that is insufficient for detailed examination.</span></p>
			<p class="em-only_endmatter-answers">&#9;8.&#9;<span class="CharOverride-10">b.</span><span class="CharOverride-9"> In the Ocular Hypertension Treatment Study (OHTS), a visual field defect was defined as the presence of a Pattern Standard Deviation (PSD) with </span><span class="CharOverride-1">P </span><span class="CharOverride-9">&lt; 5% or the presence of a Glaucoma Hemifield Test (GHT) with a result outside normal limits; the abnormality had to be present in 3 consecutive visual field tests.</span></p>
			<p class="em-only_endmatter-answers">&#9;9.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> </span><span class="CharOverride-1">CYP1B1</span><span class="CharOverride-9"> is associated with primary congenital glaucoma; </span><span class="CharOverride-1">FOXC1, </span><span class="CharOverride-9">with iridogoniodysgenesis; and </span><span class="CharOverride-1">PITX2, </span><span class="CharOverride-9">with Rieger syndrome. Pseudoexfoliation syndrome is associated with </span><span class="CharOverride-1">LOXL1</span><span class="CharOverride-9"> mutations at 15q24. </span></p>
			<p class="em-only_endmatter-answers">&#9;10.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> While choices a, b, and d may all cause glaucoma associated with primary or metastatic tumors of the ciliary body, direct invasion of the anterior chamber angle is the most common cause in these cases.</span></p>
			<p class="em-only_endmatter-answers ParaOverride-11">&#9;11.&#9;<span class="CharOverride-10">d.</span><span class="CharOverride-9"> In a mature or hypermature cataract, soluble lens protein molecules are released through microscopic openings in the lens capsule into the anterior chamber. Secondary open-angle glaucoma (OAG) may develop as lens proteins, phagocytizing macrophages, and other inflammatory debris obstruct the trabecular meshwork. Medications should be used to treat the IOP elevation; however, definitive therapy requires cataract extraction. </span></p>
			<p class="em-only_endmatter-answers-cont">In phacomorphic glaucoma, a large, intumescent lens induces angle-closure glaucoma (ACG). Lens particle glaucoma occurs when lens cortex particles obstruct the trabecular meshwork following disruption of the lens capsule with cataract extraction or ocular trauma. Ectopia lentis refers to displacement of the lens from its normal anatomical position.</p>
			<p class="em-only_endmatter-answers">&#9;12.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> Bilateral angle closure is not common and is especially uncommon in eyes with a normal axial length. The presentation of bilateral angle closure should strongly suggest uveal effusions due to use of a systemic medication, most commonly topiramate. </span></p>
			<p class="em-only_endmatter-answers">&#9;13.&#9;<span class="CharOverride-10">d.</span><span class="CharOverride-9"> Laser iridotomy is useful for treating angle closure when there is an element of pupillary block (eg, as in phacomorphic glaucoma). Iridotomy is of no benefit when angle closure is caused by other mechanisms and may exacerbate the condition if outflow is further diminished by the inflammation that usually occurs as a result of</span><span class="CharOverride-10"> </span><span class="CharOverride-9">the procedure.</span></p>
			<p class="em-only_endmatter-answers">&#9;14.&#9;<span class="CharOverride-10">a.</span><span class="CharOverride-9"> In chronic primary angle closure (PAC) with relative pupillary block, gonioscopic findings are the key to diagnosis and management. IOP may be normal or elevated. In an eye with a narrow angle, the presence of elevated pressure alone is not an indication for laser iridotomy. In this case, coexisting OAG may be causing the IOP elevation, not the narrow angle. The extent of visual field loss or optic nerve damage does not indicate whether an iridotomy is needed. In patients with appositional angle closure or areas of peripheral anterior synechiae with relative pupillary block, the risk of chronic angle closure developing is high; thus, these patients should have a laser iridotomy.</span></p>
			<p class="em-only_endmatter-answers">&#9;15.&#9;<span class="CharOverride-10">c. </span><span class="CharOverride-9">Elevation of IOP occurs with plateau iris syndrome independent of pupillary block and may occur despite a patent iridotomy.</span></p>
			<p class="em-only_endmatter-answers">&#9;16.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> Cataract extraction would not be expected to improve control of IOP in an eye with blunt trauma and direct trabecular damage. Angle recession may be present and would be evidence of trabecular damage. Phacodonesis is evidence of zonular disruption. In this patient, the lens is not contributing to the IOP elevation. In chronic primary ACG, relative pupillary block is induced by the tension of the iris sphincter muscle against the lens, which is positioned slightly anteriorly, in an eye with a relatively short axial length. Cataract surgery may improve glaucoma control or may completely eliminate glaucoma in these eyes. In phacolytic glaucoma, proteinaceous lens material that is released through microscopic openings in the lens capsule and engulfed by macrophages clogs the trabecular meshwork and causes secondary elevation of IOP. Cataract surgery may successfully treat this form of glaucoma. In microspherophakia, the abnormal, spherical shape of the lens induces pupillary block, which a laser peripheral iridotomy or lens removal would be expected to relieve.</span></p>
			<p class="em-only_endmatter-answers">&#9;17.&#9;<span class="CharOverride-10">a.</span><span class="CharOverride-9"> In children younger than 3 years, the sclera is elastic and will stretch if IOP is not well controlled. This can result in increased axial length despite a good pressure during examination under anesthesia. Corneal thickness decreases as corneal edema resolves and, once stable, is often less than the average central corneal thickness. The angle can further develop as a child ages, but this does not indicate poor pressure control. Myopia in congenital glaucoma is not necessarily an axial myopia. </span></p>
			<p class="em-only_endmatter-answers">&#9;18.&#9;<span class="CharOverride-10">d.</span><span class="CharOverride-9"> Patients with congenital glaucoma require lifelong monitoring, as relapses may occur even decades after initial surgery. These patients may also have postoperative complications, amblyopia, strabismus, corneal decompensation, cataracts, and other problems that will need to be managed over a lifetime. </span></p>
			<p class="em-only_endmatter-answers">&#9;19.&#9;<span class="CharOverride-10">a.</span><span class="CharOverride-9"> Brimonidine has been shown to cause systemic hypotension and apnea in children younger than 2 years. This drug is relatively contraindicated in older children.  </span></p>
			<p class="em-only_endmatter-answers">&#9;20.&#9;<span class="CharOverride-10">a. </span><span class="CharOverride-9">α</span><span class="CharOverride-13">2</span><span class="CharOverride-9">-Selective adrenergic agonists have been reported to cause severe, life-threatening apnea, central nervous system depression, and bradycardia in infants and children. These agents can cross the blood–brain barrier, particularly in infants. They are contraindicated for use in young children and should be avoided in nursing mothers. </span></p>
			<p class="em-only_endmatter-answers">&#9;21.&#9;<span class="CharOverride-10">c. </span><span class="CharOverride-9">Timolol, carteolol, and levobunolol are nonselective β-adrenergic antagonists (β-blockers).</span><span class="CharOverride-9"> β</span><span class="CharOverride-13">2</span><span class="CharOverride-9"> receptors are present in bronchial smooth muscle cells, where their inhibition may result in bronchospasm. The only topical ocular hypotensive β-blocker that is relatively <br />β</span><span class="CharOverride-13">1</span><span class="CharOverride-9"> selective is betaxolol; it is thus less likely to result in pulmonary adverse effects. The nonselective agents are more effective in lowering IOP than is betaxolol.</span></p>
			<p class="em-only_endmatter-answers ParaOverride-11">&#9;22.&#9;<span class="CharOverride-10">d.</span><span class="CharOverride-9"> Suprachoroidal hemorrhage can be one of the most devastating complications of trabeculectomy. Bleeding originates from the short or long posterior ciliary arteries as they enter the suprachoroidal space from the intrascleral canal. Delayed suprachoroidal hemorrhage is usually preceded by hypotony and the development of serous ciliochoroidal effusions, which stretch and rupture one of the vessels where the vessel bridges the suprachoroidal space. </span></p>
			<p class="em-only_endmatter-answers-cont">Conditions associated with an increased risk of suprachoroidal hemorrhage include high myopia, aphakia or pseudophakia, hypotony, prior vitrectomy, advanced age, systemic<span class="CharOverride-10"> </span><span class="CharOverride-9">hypertension, anticoagulant therapy, and history of suprachoroidal hemorrhage in the fellow eye. The Fluorouracil Filtering Surgery Study found that the risk of suprachoroidal hemorrhage was strongly associated with the level of preoperative IOP and the magnitude of IOP reduction. Reducing the IOP as much as possible before filtering surgery and decreasing the magnitude of the immediate IOP reduction through the use of releasable sutures or laser suture lysis can help reduce the risk of this complication.</span></p>
			<p class="em-only_endmatter-answers">&#9;23.&#9;<span class="CharOverride-10">d.</span><span class="CharOverride-9"> Studies show that 3–5 years following laser trabeculoplasty, 50% of treated patients have </span><span class="CharOverride-9">a lower IOP.  </span></p>
			<p class="em-only_endmatter-answers ParaOverride-11">&#9;24.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> All of these patients are good candidates for a tube shunt, as all patients listed have indications for a tube shunt. However, the patient who previously had a failed trabeculectomy without antifibrotics is the one most likely to have a successful trabeculectomy with mitomycin C. The Fluorouracil Filtering Surgery Study found that use of 5-fluorouracil increases the likelihood of success of a trabeculectomy, and subsequent studies have found that mitomycin C increases success rates more than 5-fluorouracil does. </span></p>
			<p class="em-only_endmatter-answers-cont">An aphakic patient is likely to have scleral scarring from surgery to remove the cataract, and contact lens wear is a risk factor for bleb-related infections. Neovascular glaucoma and uveitic glaucoma are associated with inflammation, which lowers the success rate of trabeculectomy with or without antifibrotic use.</p>
			<p class="em-only_endmatter-answers">&#9;25.&#9;<span class="CharOverride-10">c.</span><span class="CharOverride-9"> Laser trabeculoplasty (LTP) can be used as primary or adjunct therapy in patients with open angles. If the pressure needs to be lowered but the patient cannot tolerate multiple medications, LTP is a good option. LTP is less effective in aphakic and pseudophakic patients than in phakic patients. A patient with a small central island of vision who is on maximally tolerated medical therapy is at risk of vision loss if there is a significant IOP spike. LTP is contraindicated in uveitic glaucoma, because the angle is altered in eyes with a history of inflammation and studies have shown low success rates in these patients.</span></p>
		</div>
		<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet"></span> Study Questions</p>
		</div>
		<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhr">Study Questions <span class="rh-bullet">d</span>  </p>
		</div>
		<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet"></span> Study Questions</p>
		</div>
		<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhr">Study Questions <span class="rh-bullet">d</span>  </p>
		</div>
		<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet"></span> Answers</p>
		</div>
		<div id="_idContainer007" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhr"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" /></p>
		</div>
		<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet"></span> Answers</p>
		</div>
	</body>
</html>
